Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial studies how well imlunestrant and abemaciclib work in treating patients with estrogen receptor positive (ER+) breast cancer who have tumor remaining in the blood following treatment (minimal residual disease). Estrogen can cause the growth of breast cancer cells. Imlunestrant lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Imlunestrant and abemaciclib may be effective in treating patients with ER+ breast cancer who have minimal residual disease.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie raka piersi z dodatnimi receptorami na estrogeny (co najmniej 10% komórek) i ujemnymi receptorami HER2
- •Wczesny lub lokalnie zaawansowany rak piersi (stopień I-III)
- •Wykrycie śladowych ilości komórek nowotworowych w krwi (ciDNA) w ciągu ostatnich 6 miesięcy
- •Brak objawów nawrotu choroby stwierdzonych w badaniu klinicznym lub obrazowym
- •Dostępny materiał tkankowy z biopsji lub operacji do badań laboratoryjnych
- •Brak innego raka w ciągu ostatnich 5 lat (z wyłączeniami dla białaczki in situ i czerniaków)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, United States
Trial contact
Ruth Gonzalez
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.